2nd Annual Alzheimer’s Drug Development Summit

November 6 - 7, 2008
Washington, DC


Recent studies show that a potential Alzheimer’s pandemic could potentially bankrupt the United States Healthcare system. However, the successful development of a disease-modifying drug for Alzheimer’s could potentially save the U.S. Healthcare system an estimated $4.0 trillion dollars. Building off of the success of our inaugural conference, CBI’s Second Annual Alzheimer’s Drug Development Summit examines the latest disease modifying therapies and pre-symptomatic approaches for Alzheimer’s.

Hear Three Case Studies on the Latest AD Treatment Initiatives:

*
An update on the development of CTS21166 an Oral Beta Secretase Inhibitor
*
Data that supports the notion of a metabolic subtype of AD patients
*
Description of the aims and structure of the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Click here to see the Agenda

Distinguished Speakers

*
Barry J. Bedell, M.D., Ph.D.,Chief Operating Officer and Chief Science Officer, Biospective Inc.; Director, Small Animal Imaging Lab, Montreal Neurological Institute/McGill University
*
Andrew D. Blackwell, Ph.D., Honorary Visiting Research Associate, School of Clinical Medicine, Department of Psychiatry, University of Cambridge; Chief Scientific Officer, Cambridge Cognition Ltd.
*
Neil S. Buckholtz, Ph.D., Chief, Dementias of Aging Branch Division of Neuroscience, National Institute on Aging, National Institutes of Health
*
Marc Cantillon, M.D., Senior Medical Director, CNS Clinical Research, Schering Plough Research Institute
*
Maria C.Carrillo, Ph.D., Director, Medical & Scientific Relations, Alzheimer’s Association
*
Anne M. Fagan, Ph.D., Research Associate Professor, Dept. of Neurology, Washington University School of Medicine
*
Howard Fillit, M.D., Executive Director, The Alzheimer’s Drug Discovery Foundation
*
Michael Gold, MS, M.D., Clinical Vice President, Neurology, GlaxoSmithKline
*
Carl F. Grove, Vice President, Development Operationsand Regulatory Affairs, CoMentis, Inc.
*
Louis Kirby, M.D., Chief Medical Officer, Provista Life Sciences
*
David Lee, MPA, Deputy Director, The Biomarkers Consortium, Foundation for the National Institutes of Health
*
Michael F. Murphy, M.D., Ph.D., Chief Medical and Scientific Officer, Worldwide Clinical Trials (WCT)
*
Peter Reed, Ph.D., Senior Director, Programs, Alzheimer’s Association
*
Eric Siemers, M.D., Medical Director, Alzheimer’s Disease Team, Eli Lilly and Company
*
Keith Wesnes, Ph.D., Chief Executive and Scientific Director, CDR Ltd, UK; Northumbria University, UK; Swinburne University, Australia
*
Kenton H. Zavitz, Ph.D., Senior Director of Clinical Affairs, Myriad Pharmaceuticals, Inc.

Meeting Registration